Skip to content
CancerIndex

Publication

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.

Authors not recorded

Clin Cancer Res2023PMID 36853016PMC10102836stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (8)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 8

Curated evidence

Evidence citing this paper (1)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
36853016
Run
ING-CIVIC-20260908-000001
Open at source CuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
CCND1 Amplification + CCND2 Amplification + CCND3 AmplificationCCND1CCND2CCND31
PalbociclibMalignant NeoplasmALIASPredictiveBDoes Not Support Sensitivity Response4accepted
EID11673

This Phase 2 NCI-MATCH Trial subprotocol Z1B was conducted in 32 patients with either CCND1, 2 or 3 amplification, and were treated with Palbociclib. Squamous cell lung cancer (n=5), adenocarcinoma of… (full text at CIViC)

PMID 36853016 · Clark et al., 2023 · Open in CIViC

civic